# Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease

> **NCT05422885** · PHASE1,PHASE2 · COMPLETED · sponsor: **Lewis Lipsitz** · enrollment: 15 (actual)

## Conditions studied

- Aging

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Quercetin

## Key facts

- **NCT ID:** NCT05422885
- **Lead sponsor:** Lewis Lipsitz
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-20
- **Primary completion:** 2024-01-24
- **Final completion:** 2024-01-24
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05422885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05422885, "Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05422885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*